抗PLA2R抗体不同表位定量检测及其在原发性膜性肾病中的临床应用
本研究建立时间分辨荧光免疫分析法(TRFIA)定量检测靶向M型磷脂酶A2受体(PLA2R)不同表位的IgG/IgG4自身抗体,并在59例原发性膜性肾病(PMN)患者血清中检测。结果显示抗PLA2R IgG4检测较IgG更敏感地筛查患者对PLA2R结构域的反应性,且PLA2R表位扩展与PMN患者病情严重程度相关。
要点
- 建立的TRFIA可定量检测PLA2R及其表位特异性IgG和IgG4。
- 59例PMN患者中抗PLA2R IgG阳性46例,抗PLA2R IgG4阳性54例。
- 检出两个或以上表位的患者肾损伤更严重。
核心结论
- 成功建立PLA2R结构域特异性IgG/IgG4 TRFIA,抗PLA2R IgG4检测能更敏感地筛查患者对PLA2R结构域的反应性。
- PLA2R表位扩展与PMN患者病情严重程度相关。
研究设计与样本
- 研究建立TRFIA方法,采用铕标记抗人IgG/IgG4抗体、重组蛋白和患者血清进行检测。
- 检测59例PMN患者血清中靶向PLA2R及其表位的IgG/IgG4水平,并评估PLA2R表位扩展与病情严重程度的关系。
主要发现
- 59例PMN患者中,抗PLA2R IgG阳性46例,抗PLA2R IgG4阳性54例。
- PLA2R抗体水平与PMN患者病情严重程度强相关。
- 检出两个或以上表位的患者肾损伤更严重。
临床怎么用
- 抗PLA2R IgG4检测可用于更敏感地筛查PMN患者对PLA2R结构域的反应性。
- 检测PLA2R表位扩展有助于评估PMN患者病情严重程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to establish time-resolved fluorescence immunoassays to quantitatively detect the autoantibodies targeting different epitopes of M-type phospholipase A2 receptor (PLA2R) and evaluate its clinical application in primary membranous nephropathy (PMN). METHODS: PLA2R and its reactive epitope-specific IgG/IgG4 time-resolved fluorescence immunoassays (TRFIAs) were established using europium-labeled anti-human IgG/IgG4 antibodies, recombinant proteins, and patient serum. The levels of IgG/IgG4 targeting PLA2R and its epitopes in PMN patient serum were detected, and the relationship between epitope spreading of PLA2R and the severity of patients with PMN was evaluated. RESULTS: The TRFIAs established in this study could quantitatively detect PLA2R and its epitope-specific IgG and IgG4. Sera from 59 patients with PMN were subjected to detection using anti-PLA2R IgG and anti-PLA2R IgG4. Among them, 46 and 54 patients were found positive for PLA2R antibodies, respectively. Moreover, the levels of PLA2R antibodies were strongly correlated with the severity of patients with PMN. Patients who were detected to have two or more epitopes had more serious renal injury. CONCLUSIONS: PLA2R domain-specific IgG/IgG4 TRFIAs were established in this study, and detection with anti-PLA2R IgG4 could more sensitively screen the reactivity of patients to the PLA2R domain. Moreover, detection epitope spreading of PLA2R was confirmed which is related to the severity of patients with PMN.
引用
- Qin Y, Wu Q, Sheng H, et al. Quantitative detection of anti-PLA2R antibodies targeting different epitopes and its clinical application in primary membranous nephropathy. Clin Chem Lab Med. 2022. PMID: 36351699. doi:10.1515/cclm-2022-0720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。